neximmune inc shares jumped 31 to 192 extending gains made in afterhours trading thursday after the company said it received ind clearance for nexi003 from the food and drug administration nexi003 is being developed for patients with relapsed or refractory human papillomavirusrelated cancers the clinicalstage biotechnology company said thursday the phase 1 trial will enroll patients at multiple clinical sites across the us neximmune said the stock opened friday at 190 and touched as high as 218 the stock had traded 452 million shares as of 1133 am edt compared with its 65day average volume of 206160 shares